In a patient with autoimmune hepatitis on mycophenolate mofetil, can a Janus kinase (JAK) inhibitor be used to control his ulcerative colitis?

Can JAK Inhibitors Be Used for Ulcerative Colitis in a Patient on Mycophenolate Mofetil for Autoimmune Hepatitis?

Yes, JAK inhibitors can be used to treat ulcerative colitis in this patient, but this combination requires careful consideration of cumulative immunosuppression risks, particularly serious infections, and should ideally be done with close monitoring and risk mitigation strategies.

Rationale and Evidence-Based Approach

JAK Inhibitors Are Effective for Ulcerative Colitis

The 2024 AGA guidelines strongly support JAK inhibitor use in moderate-to-severe UC. The AGA recommends using higher efficacy medications including upadacitinib, or intermediate efficacy medications including tofacitinib and filgotinib for UC management 1. These agents demonstrate significant improvements in clinical remission (RR 2.48), endoscopic remission (RR 3.52), and mucosal healing compared to placebo 2.

Among the three approved JAK inhibitors:

• Upadacitinib provides the highest efficacy for both induction and maintenance of remission 3
• Filgotinib demonstrates the most favorable safety profile 3
• Tofacitinib offers intermediate efficacy with established real-world experience 4

The Combination Concern: Dual Immunosuppression

The critical issue here is combining two immunosuppressive agents - mycophenolate mofetil (MMF) for AIH and a JAK inhibitor for UC. While guidelines don't explicitly address this specific combination, several principles apply:

MMF's immunosuppressive effects include:

• Increased risk of opportunistic infections including CMV, herpes viruses, and fungal infections 5
• Risk of progressive multifocal leukoencephalopathy (PML) and polyomavirus-associated nephropathy 5
• Bone marrow suppression potential 5

JAK inhibitors carry their own risks:

• Increased infections, particularly herpes zoster and tuberculosis reactivation 6, 7
• Venous thromboembolism (particularly with tofacitinib at higher doses) 1
• Cardiovascular events in high-risk patients 6

Clinical Decision Algorithm

Step 1: Assess UC Disease Severity and Prior Treatment

• If moderate-to-severe UC with prior biologic failure → JAK inhibitors are appropriate per FDA labeling 1
• If biologic-naïve → FDA recommends JAK inhibitors after TNF antagonist failure, though AGA guidelines are less restrictive 1

Step 2: Risk Stratification for Combined Immunosuppression

Proceed with JAK inhibitor if:

• Patient is <65 years old
• No history of recurrent serious infections
• No cardiovascular risk factors or prior thrombotic events
• Adequate vaccination status (especially herpes zoster)
• Negative screening for latent TB and hepatitis B 7

Exercise extreme caution or consider alternatives if:

• Age ≥65 years with cardiovascular comorbidities
• History of recurrent infections on MMF alone
• Prior thrombotic events
• Active or recent malignancy 6, 7

Step 3: Agent Selection Based on Safety Profile

Given the patient is already on MMF, prioritize filgotinib for its superior safety profile 3, unless disease severity demands the higher efficacy of upadacitinib 3. Avoid tofacitinib 10mg BID maintenance due to higher thromboembolism risk 1.

Step 4: Mandatory Risk Mitigation

Before initiating JAK inhibitor:

• Screen and treat latent TB 7
• Vaccinate against herpes zoster (if not contraindicated) 7
• Screen for hepatitis B and manage if positive 5, 7
• Baseline lipid panel and liver function tests
• Assess cardiovascular risk factors 6

During treatment:

• Monitor for infections vigilantly - both opportunistic (from MMF) and typical bacterial/viral (from JAK inhibitor)
• Regular CBC monitoring for cytopenias
• Lipid monitoring every 3-6 months
• Consider prophylactic antivirals if herpes zoster vaccination not feasible 6

Alternative Consideration: Sequential Rather Than Concurrent Therapy

The 2024 AGA guidelines note that combination therapy with immunomodulators is primarily studied with TNF antagonists, not JAK inhibitors 1. There is a knowledge gap regarding non-TNF biologics combined with immunomodulators 1.

If the patient's AIH is well-controlled on MMF, consider whether:

1. MMF could be tapered or discontinued before starting JAK inhibitor (requires hepatology consultation)
2. Alternative UC therapies with different safety profiles could be used (vedolizumab has gut-selective mechanism, ustekinumab has favorable safety in pregnancy/long-term use 8)

Common Pitfalls to Avoid

1. Don't assume all JAK inhibitors have identical safety profiles - selectivity matters clinically 3
2. Don't use tofacitinib 10mg BID for maintenance - de-escalate to 5mg BID after induction to minimize thromboembolism risk 1
3. Don't skip pre-treatment screening - latent TB reactivation and herpes zoster are preventable complications 7
4. Don't ignore the FDA labeling restriction - in the US, JAK inhibitors are labeled for use after TNF antagonist failure 1

Monitoring Strategy

• Weeks 0-8 (Induction): CBC, CMP, and infection surveillance every 2-4 weeks
• Months 3-12: CBC, CMP, lipids every 3 months
• Ongoing: Maintain high suspicion for opportunistic infections given dual immunosuppression
• Coordinate care between gastroenterology and hepatology to optimize both conditions

The combination is feasible but requires individualized risk assessment, meticulous pre-treatment preparation, agent selection favoring safety (filgotinib), and intensive monitoring for the additive immunosuppressive effects.